TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30192802

Group type: EXPERIMENTAL
Intervention: Cetuximab treatment during stimulation with IFNγ and TNFα
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemical inhibition of EGFR signaling (using MEK1/2 inhibitor PD98059 and JNK inhibitor SP600125)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination treatment with cetuximab and MEK1/2 or JNK inhibitor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stimulation with IFNγ and TNFα
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blocking of EGFR with cetuximab
Number of subjects: 0
Study: 27342447

Group type: EXPERIMENTAL
Intervention: Ketamine (100 ng/mL target plasma concentration)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (intravenous saline)
Number of subjects: 27
Study: 24621831

Group type: COMPARATOR
Intervention: Normal sodium (Dex‐0 group, n=319)
Number of subjects: 954

Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.1 mg/kg (Dex‐1 group, n=320)
Number of subjects: 954

Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.2 mg/kg (Dex‐2 group, n=315)
Number of subjects: 954
Study: 22874685

Group type: EXPERIMENTAL
Intervention: Biliary stent
Number of subjects: 60

Group type: COMPARATOR
Intervention: T-tube
Number of subjects: 60
Study: 20398482

Group type: EXPERIMENTAL
Intervention: Benidipine (8 mg/d)
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Valsartan (80 mg/d)
Number of subjects: 236
Study: 17335828

Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gemfibrozil with weight loss
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gemfibrozil with diabetes or hyperinsulinemia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gemfibrozil without weight loss
Number of subjects: 0
Study: 15880810

Group type: EXPERIMENTAL
Intervention: Intramuscular gold
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 65
Study: 11689270

Group type: EXPERIMENTAL
Intervention: Oral HRT
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Transdermal HRT
Number of subjects: 33

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 33
Study: 9632032

Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg daily
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Paroxetine 40 mg daily
Number of subjects: 99
Study: 7930052

Group type: EXPERIMENTAL
Intervention: Low-psychopathy group
Number of subjects: 54

Group type: COMPARATOR
Intervention: High-psychopathy group
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Antisocial behavior factor of psychopathy
Number of subjects: 54
Study: 3284322

Group type: EXPERIMENTAL
Intervention: Propranolol (60 or 80 mg 3 times daily)
Number of subjects: 1650
Study: 1983801

Group type: EXPERIMENTAL
Intervention: Gastric Lavage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Activated Charcoal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ipecacuanha
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 1095307

Group type: EXPERIMENTAL
Intervention: Bromhexine, 16 mg, 3-times daily for 3 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Bromhexine and Placebo
Number of subjects: 36
Study: 30772115

Group type: EXPERIMENTAL
Intervention: Health Research Engagement Intervention
Number of subjects: 133

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Qualitative interviews
Number of subjects: 133
Study: 28124536

Group type: EXPERIMENTAL
Intervention: Intravesical chondroïtin sulphate (CS) 2%
Number of subjects: 36

Group type: COMPARATOR
Intervention: Intravesical dimethyl sulphoxide (DMSO) 50%
Number of subjects: 36
Study: 25887128

Group type: EXPERIMENTAL
Intervention: Algisite™ M (calcium alginate dressing)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cuticerin™ (smooth acetate gauze with water-repellent ointment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sorbact® (gauze mesh coated with DACC and amorphous hydrogel)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 23343804

Group type: EXPERIMENTAL
Intervention: Calcium hydroxide cement (CHC)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Glass ionomer cement (GIC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Negative control (wax)
Number of subjects: 60
Study: 20647950

Group type: EXPERIMENTAL
Intervention: High-intensity low-volume (50 km) training group (HILV-group)
Number of subjects: 26

Group type: COMPARATOR
Intervention: High-volume (70 km) low-intensity training group (HVLI-group)
Number of subjects: 26
Study: 19214143

Group type: EXPERIMENTAL
Intervention: Zileuton (5-lipoxygenase inhibitor)
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: Montelukast (cys-leukotriene receptor antagonist)
Number of subjects: 577

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 577
Study: 17264955

Group type: EXPERIMENTAL
Intervention: Oral tranexamic acid (TA)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Cultured endothelial cells treated with TA
Number of subjects: 14
Study: 15536460

Group type: EXPERIMENTAL
Intervention: Oral ALF after rifampin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oral ALF after troleandomycin (TAO)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oral ALF after grapefruit juice
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 10
Study: 11409217

Group type: EXPERIMENTAL
Intervention: Talking
Number of subjects: 64

Group type: COMPARATOR
Intervention: Counting aloud
Number of subjects: 64
Study: 9493975

Group type: EXPERIMENTAL
Intervention: CMF (Cyclophosphamide 400 mg/m2, Fluorouracil 400 mg/m2, and Methotrexate 40 mg/m2)
Number of subjects: 282

Group type: COMPARATOR
Intervention: Control arm (no adjuvant therapy)
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Mutated p53 group
Number of subjects: 282
Study: 8066587

Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decision-making participation
Number of subjects: 0
Study: 3355474

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 30691748

Group type: EXPERIMENTAL
Intervention: Traditional Dysphagia Therapy (TDT) - sensorimotor exercises and swallowing maneuvers
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual Care (UC) - diet prescription and postural changes
Number of subjects: 20
Study: 28834296

Group type: EXPERIMENTAL
Intervention: Postoperative antibiotics (group B)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Placebo (group A)
Number of subjects: 188
Study: 26890400

Group type: EXPERIMENTAL
Intervention: Ironson‐Woods Spirituality/Religiousness Index (IWSRI)
Number of subjects: 300
Study: 23646330

Group type: EXPERIMENTAL
Intervention: Modified Essix retainers
Number of subjects: 36

Group type: COMPARATOR
Intervention: Full-coverage Essix retainers
Number of subjects: 36
Study: 21750697

Group type: EXPERIMENTAL
Intervention: Rapid malaria diagnostic tests (RDTs) by community health workers (CHWs)
Number of subjects: 2930

Group type: COMPARATOR
Intervention: Clinical diagnosis (CD) by community health workers (CHWs)
Number of subjects: 2930
Study: 19396790

Group type: EXPERIMENTAL
Intervention: Selective laser trabeculoplasty (SLT)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Argon laser trabeculoplasty (ALT)
Number of subjects: 120
Study: 16882893

Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 21

Group type: COMPARATOR
Intervention: Bupivacaine and betamethasone
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Bupivacaine (alone or in combination with betamethasone)
Number of subjects: 21
Study: 15361745

Group type: EXPERIMENTAL
Intervention: Face-to-face interviews
Number of subjects: 34

Group type: COMPARATOR
Intervention: Phone interviews
Number of subjects: 34
Study: 11726064

Group type: EXPERIMENTAL
Intervention: Local anaesthesia
Number of subjects: 2

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 2
Study: 9204223

Group type: COMPARATOR
Intervention: Placebo run-in period
Number of subjects: 391
Study: 7956538

Group type: EXPERIMENTAL
Intervention: Injection of low dosed or low molecular heparin into the contralateral abdominal wall
Number of subjects: 108

Group type: COMPARATOR
Intervention: Injection of low dosed or low molecular heparin into the thigh
Number of subjects: 108
Study: 2955717

Group type: EXPERIMENTAL
Intervention: 0.025 mg/kg ATR
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 0.05 mg/kg DTC
Number of subjects: 44

Group type: COMPARATOR
Intervention: Saline (NS)
Number of subjects: 44
Study: 30161248

Group type: EXPERIMENTAL
Intervention: Few Touch Application (mHealth intervention)
Number of subjects: 101
Study: 25861808

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (5000 IU/day)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 24371304

Group type: EXPERIMENTAL
Intervention: Amantadine (continuing group)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo (discontinuing group)
Number of subjects: 57
Study: 22326387

Group type: EXPERIMENTAL
Intervention: Hypocaloric diet (HD)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Regular diet (RD)
Number of subjects: 96
Study: 19473893

Group type: EXPERIMENTAL
Intervention: i-Scan
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Chromoendoscopy (Methylene blue 0.1%)
Number of subjects: 69

Group type: COMPARATOR
Intervention: HD+ alone
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Chromoendoscopy
Number of subjects: 69
Study: 18578171

Group type: EXPERIMENTAL
Intervention: Gaseous ozone (Healozone, KaVo 1600 ppm) for 60 seconds
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Comparison of test and control teeth
Number of subjects: 31
Study: 16225359

Group type: EXPERIMENTAL
Intervention: Ziconotide (PRIALT®)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11955537

Group type: EXPERIMENTAL
Intervention: Off-pump surgery
Number of subjects: 401
Study: 10865690

Group type: EXPERIMENTAL
Intervention: Prepared group
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 86
Study: 8532902

Group type: EXPERIMENTAL
Intervention: Internal mammary chain irradiation (IMC‐RT)
Number of subjects: 270

Group type: COMPARATOR
Intervention: No internal mammary chain irradiation (no‐IMC‐RT)
Number of subjects: 270
Study: 2184938

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Captopril combined with diltiazem
Number of subjects: 28

Group type: COMPARATOR
Intervention: Diltiazem
Number of subjects: 28
Study: 40816

Group type: EXPERIMENTAL
Intervention: Phenazepam (0.0025 mg/kg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Diazepam (0.005 mg/kg)
Number of subjects: 32
Study: 31589776

Group type: EXPERIMENTAL
Intervention: Denosumab (n = 32)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo (n = 32)
Number of subjects: 64
Study: 28390867

Group type: EXPERIMENTAL
Intervention: MEDI2070 (700 mg) at weeks 0 and 4, followed by open-label MEDI2070 (210 mg) subcutaneously every 4 weeks from weeks 12 to 112
Number of subjects: 119

Group type: COMPARATOR
Intervention: Open-label MEDI2070 after placebo
Number of subjects: 119
Study: 26303135

Group type: EXPERIMENTAL
Intervention: Home-based parenting support for attachment, delivered until 6 months postpartum
Number of subjects: 449

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 449
Study: 24859954

Group type: EXPERIMENTAL
Intervention: Carbon nanoparticle group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 22642182

Group type: EXPERIMENTAL
Intervention: 15-session MOHO program
Number of subjects: 220

Group type: COMPARATOR
Intervention: 15-session crafts program or no treatment
Number of subjects: 220
Study: 20673485

Group type: EXPERIMENTAL
Intervention: Post-chemotherapy tumor extent (GTV-T) irradiation
Number of subjects: 77

Group type: COMPARATOR
Intervention: Pre-chemotherapy tumor extent (GTV-T) irradiation
Number of subjects: 77
Study: 18397701

Group type: EXPERIMENTAL
Intervention: Cinacalcet (30 - 180 mg/day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 15849845

Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg IV
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (2 ml saline IV)
Number of subjects: 40
Study: 12418585

Group type: EXPERIMENTAL
Intervention: Inhaled oxitropium bromide 200 microg
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Sustained-release oral theophylline 300 mg
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Combination of oxitropium bromide and theophylline
Number of subjects: 236

Group type: COMPARATOR
Intervention: Control group (theophylline alone)
Number of subjects: 236
Study: 10628627

Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 102

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 102
Study: 7862382

Group type: EXPERIMENTAL
Intervention: Closure of the Camper fascia
Number of subjects: 245

Group type: COMPARATOR
Intervention: No closure of Camper fascia
Number of subjects: 245
Study: 1412152

Group type: EXPERIMENTAL
Intervention: Desmopressin (0.3 micrograms/kg, i.v.)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 4014796

Group type: EXPERIMENTAL
Intervention: 0.2 mg ergometrine by slow intravenous injection
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: 5 units oxytocin in intravenous infusion throughout the procedure
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control group (no oxytocic drugs)
Number of subjects: 113
Study: 30796153

Group type: EXPERIMENTAL
Intervention: Percutaneous computed tomography‐guided cordotomy
Number of subjects: 16

Group type: COMPARATOR
Intervention: Continued interdisciplinary palliative care
Number of subjects: 16
Study: 30427933

Group type: EXPERIMENTAL
Intervention: Early endurance and resistance training combined with mobilisation
Number of subjects: 115

Group type: COMPARATOR
Intervention: Standard physiotherapy including early mobilisation
Number of subjects: 115
Study: 26370095

Group type: EXPERIMENTAL
Intervention: Financial incentives of up to £400 vouchers contingent upon smoking cessation
Number of subjects: 612

Group type: COMPARATOR
Intervention: Usual cessation support
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: Financial incentives of up to £400 vouchers
Number of subjects: 612
Study: 24287124

Group type: EXPERIMENTAL
Intervention: Web-based intervention (experimental group 1)
Number of subjects: 2001

Group type: EXPERIMENTAL
Intervention: Web-based intervention supplemented with text messages (experimental group 2)
Number of subjects: 2001

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2001
Study: 23725092

Group type: EXPERIMENTAL
Intervention: Medical + Lifestyle Programme (MLP)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Medical Programme (MP)
Number of subjects: 314
Study: 21436229

Group type: EXPERIMENTAL
Intervention: Mitoxantrone (MITOX) monthly (12 mg/m²; maximum 20 mg) combined with 1 g of methylprednisolone (MP) for 6 months followed by interferon beta-1b (IFN) for the last 27 months
Number of subjects: 109

Group type: COMPARATOR
Intervention: Interferon beta-1b (IFN) for 3 years combined with 1 g of methylprednisolone (MP) monthly for the first 6 months
Number of subjects: 109
Study: 19959915

Group type: EXPERIMENTAL
Intervention: Exposure to sunlight with calcium supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Menatetrenone (vitamin K2) plus calcium and vitamin D supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risedronate plus calcium and vitamin D supplementation
Number of subjects: 0
Study: 17511904

Group type: EXPERIMENTAL
Intervention: Surgical treatment using modified Luque III instrumentation
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Surgical treatment with various fixation techniques
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Preoperative scoliosis ranking
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Surgical treatment with anterior and posterior approaches
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Overall complication rate
Number of subjects: 120
Study: 15356403

Group type: EXPERIMENTAL
Intervention: Levormeloxifene (5 mg/kg/day)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Levormeloxifene (0.2 mg/kg/day)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Estrogen
Number of subjects: 301

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Sham operation
Number of subjects: 301
Study: 11438314

Group type: EXPERIMENTAL
Intervention: 0.625 CEE
Number of subjects: 749

Group type: EXPERIMENTAL
Intervention: 0.625 CEE/2.5 MPA
Number of subjects: 749

Group type: EXPERIMENTAL
Intervention: 0.45 CEE
Number of subjects: 749

Group type: EXPERIMENTAL
Intervention: 0.45 CEE/2.5 MPA
Number of subjects: 749

Group type: EXPERIMENTAL
Intervention: 0.45 CEE/1.5 MPA
Number of subjects: 749

Group type: EXPERIMENTAL
Intervention: 0.3 CEE
Number of subjects: 749

Group type: EXPERIMENTAL
Intervention: 0.3 CEE/1.5 MPA
Number of subjects: 749

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 749
Study: 9679514

Group type: EXPERIMENTAL
Intervention: High-knowledge (HK) readers received passage titles that clarified the content.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-knowledge (LK) readers did not receive passage titles.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Older LK readers who were above average in recall.
Number of subjects: 0
Study: 7726670

Group type: EXPERIMENTAL
Intervention: Beger technique
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Frey technique
Number of subjects: 42
Study: 2033963

Group type: EXPERIMENTAL
Intervention: Daunorubicin (DNR)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Mitoxantrone (DHAD)
Number of subjects: 164

Group type: COMPARATOR
Intervention: CNS prophylaxis with intermediate dose methotrexate (MTX) and intrathecal MTX
Number of subjects: 164
Study: 6803279

Group type: EXPERIMENTAL
Intervention: Imipramine (50‐200 mg/day)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Nortriptyline (40‐100 mg/day)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Imipramine with perphenazine (8‐16 mg/day)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Nortriptyline with perphenazine (8‐16 mg/day)
Number of subjects: 17
Study: 30178432

Group type: EXPERIMENTAL
Intervention: High-Intensity Laser Therapy (HILT)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Conventional Physical Therapy (CPT)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Exercise Therapy (ET)
Number of subjects: 93
Study: 28651648

Group type: EXPERIMENTAL
Intervention: Physiologic oxygenation (FIO2 necessary to maintain arterial hemoglobin saturation of 95 to 97%)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Hyper‐oxygenation (FIO2 = 1.0)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Physiologic oxygenation
Number of subjects: 200

Group type: COMPARATOR
Intervention: Hyper‐oxygenation
Number of subjects: 200
Study: 26436533

Group type: EXPERIMENTAL
Intervention: Adaptive truncated weighting method for estimating weights in marginal structural models (MSMs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional time-dependent Cox models
Number of subjects: 0
Study: 23399476

Group type: EXPERIMENTAL
Intervention: Usual care with the intervention package (nurse-led consultations and peer support)
Number of subjects: 306

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Usual care with the intervention package
Number of subjects: 306
Study: 21933834

Group type: EXPERIMENTAL
Intervention: Refrigerator magnet and text message emphasizing benefits to society
Number of subjects: 1041

Group type: COMPARATOR
Intervention: Standard reminder regarding follow-up
Number of subjects: 1041

Group type: EXPERIMENTAL
Intervention: Telephone call from a senior female clinician and researcher
Number of subjects: 1041

Group type: COMPARATOR
Intervention: Standard Txt2stop follow-up procedures
Number of subjects: 1041
Study: 20048503

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sulphonylurea monotherapy
Number of subjects: 0
Study: 17575542

Group type: EXPERIMENTAL
Intervention: Endoscopic pancreatic function test (ePFT)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 2-hour pancreatic function test (2hPFT)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 33
Study: 14731120

Group type: EXPERIMENTAL
Intervention: High-dose interferon (IFN)-alpha 2b (10 MU/m2) thrice/weekly for 6 months
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: IFN-alpha (5 MU/m2) thrice/weekly for 6 months + Lamivudine (LAM) (4 mg/kg, max 100 mg/day) for 12 months (started simultaneously with IFN)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: IFN-alpha (5 MU/m2) thrice/weekly for 6 months + Lamivudine (LAM) (4 mg/kg, max 100 mg/day) for 12 months (started 2 months prior to IFN)
Number of subjects: 182

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 182
Study: 11477496

Group type: EXPERIMENTAL
Intervention: Low-sugar diet (LSD) providing 5% of energy from sucrose
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Sugar-containing diet (SCD) providing 10% of energy from sucrose
Number of subjects: 95
Study: 9566175

Group type: EXPERIMENTAL
Intervention: Voucher for free mammography
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (women living in the same counties without vouchers)
Number of subjects: 0
Study: 8311217

Group type: EXPERIMENTAL
Intervention: 2% lignocaine gel applied to Filshie clips
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (no lignocaine gel)
Number of subjects: 62
Study: 2031737

Group type: EXPERIMENTAL
Intervention: Booklet of advice for parents
Number of subjects: 0
Study: 6779334

Group type: EXPERIMENTAL
Intervention: d-amphetamine
Number of subjects: 10

Group type: COMPARATOR
Intervention: diazepam 2 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: diazepam 5 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: diazepam 10 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10